These results support recent data from the literature showing TK1 as a potential pharmacodynamic marker of CDK4/6 inhibition in ER+/HER2- BC [38]; indeed, TK1 synthesis is regulated by the E2F pathway [39], which represents the main target of CDK4/6 inhibitors. This evidence concerns the gene ERBB2 and breast cancer.